Envestnet Asset Management Inc. Sells 2,925 Shares of OrthoPediatrics Corp. (NASDAQ:KIDS)

Envestnet Asset Management Inc. cut its stake in OrthoPediatrics Corp. (NASDAQ:KIDS – Get Rating) by 6.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,309 shares of the company’s stock after selling 2,925 shares during the period. Envestnet Asset Management Inc. owned about 0.20% of OrthoPediatrics worth $1,800,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Point72 Hong Kong Ltd bought a new position in shares of OrthoPediatrics in the first quarter worth about $26,000. MCF Advisors LLC bought a new position in shares of OrthoPediatrics in the third quarter worth about $33,000. Almanack Investment Partners LLC. purchased a new stake in OrthoPediatrics in the third quarter worth about $34,000. HighMark Wealth Management LLC lifted its stake in OrthoPediatrics by 100.0% in the fourth quarter. HighMark Wealth Management LLC now owns 750 shares of the company’s stock worth $30,000 after acquiring an additional 375 shares during the period. Finally, Lazard Asset Management LLC purchased a new stake in OrthoPediatrics in the first quarter worth about $65,000. 97.02% of the stock is currently owned by institutional investors.

Insider Activity

In other news, SVP Joseph W. Hauser sold 2,554 shares of the company’s stock in a transaction dated Thursday, March 2nd. The shares were sold at an average price of $43.74, for a total transaction of $111,711.96. Following the transaction, the senior vice president now owns 36,144 shares in the company, valued at $1,580,938.56. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, General Counsel Daniel J. Gerritzen sold 3,315 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $44.62, for a total transaction of $147,915.30. Following the transaction, the general counsel now owns 35,527 shares in the company, valued at $1,585,214.74. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Joseph W. Hauser sold 2,554 shares of the stock in a transaction that occurred on Thursday, March 2nd. The stock was sold at an average price of $43.74, for a total transaction of $111,711.96. Following the completion of the transaction, the senior vice president now owns 36,144 shares in the company, valued at approximately $1,580,938.56. The disclosure for this sale can be found here. Insiders have sold a total of 26,761 shares of company stock worth $1,208,081 over the last 90 days. 29.50% of the stock is currently owned by corporate insiders.

OrthoPediatrics Stock Performance

KIDS stock opened at $45.25 on Friday. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of 226.25 and a beta of 0.89. The firm has a 50-day simple moving average of $45.77 and a two-hundred day simple moving average of $43.85. OrthoPediatrics Corp. has a one year low of $35.67 and a one year high of $60.75.

OrthoPediatrics (NASDAQ:KIDS – Get Rating) last released its quarterly earnings results on Tuesday, February 28th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.10). The firm had revenue of $30.99 million for the quarter, compared to analysts’ expectations of $31.01 million. OrthoPediatrics had a net margin of 2.72% and a negative return on equity of 5.32%. As a group, equities analysts predict that OrthoPediatrics Corp. will post -0.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. TheStreet lowered shares of OrthoPediatrics from a “c” rating to a “d+” rating in a research note on Wednesday, March 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $51.00 price objective on shares of OrthoPediatrics in a research note on Monday, April 17th. 1-800-FLOWERS.COM reaffirmed a “maintains” rating on shares of OrthoPediatrics in a research note on Tuesday, May 2nd. Finally, Truist Financial upped their price objective on shares of OrthoPediatrics from $53.00 to $57.00 and gave the stock a “buy” rating in a research note on Monday, April 17th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $55.33.

OrthoPediatrics Company Profile

(Get Rating)

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. The company was founded by Erin Springer Yount and Nick A.